# US 2022/0032074 A1 · Spreading depolarization and repolarization as biomarkers of neurological recovery after cardiac arrest

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0032074 A1
- Document ID: US20220032074A1
- Status: Published application
- Kind: A1
- Application number: 17/277,616
- Filed: 2019-09-23
- Published: 2022-02-03
- Earliest claimed: 2018-09-21
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Yama Akbari; Robert H. Wilson; Christian Crouzet; Bernard Choi; Bruce J. Tromberg
- Web page: https://patentgrep.com/patent/US20220032074A1

## CPC

- A61B 5/14553: {specially adapted for cerebral tissue}
- A61N 1/39044: {in combination with cardiopulmonary resuscitation [CPR] therapy}
- A61B 5/37: Intracranial electroencephalography [IC-EEG], e.g. electrocorticography [ECoG]
- A61B 5/372: Analysis of electroencephalograms
- A61B 5/4064: {Evaluating the brain (for intracranial pressure A61B5/031; for cerebral blood gases A61B5/14553; using EEG A61B5/369)}
- A61B 5/4839: {combined with drug delivery}
- A61H 31/005: {with feedback for the user}
- A61B 5/0261: {using optical means, e.g. infrared light}
- A61H 2201/5094: with patient markers
- A61H 2230/085: used as a control parameter for the apparatus
- A61H 2230/105: used as a control parameter for the apparatus
- A61H 2230/255: used as a control parameter for the apparatus
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61H: PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY (electrotherapy, magnetotherapy, radiation therapy or ultrasound therapy A61N)

## Abstract

Electrophysiologic biomarkers for prognostication of neurological outcome are described herein. An inverse correlation was found between timing of a cortical spreading depolarization (SD) wave and neurological outcome as tested at 24 hours post-CPR. Additionally, a minor image of this SD was identified as a “repolarization (RP) wave.” Quantifying features of SD and RP during cardiac arrest and cardiopulmonary resuscitation (CPR) provide important metrics for diagnosis and prognosis of neurological injury from hypoxia-ischemia and can serve as an early prognostication tool for predicting outcome at subsequent days after successful CPR. This discovery may also allow for novel therapeutic interventions to improve neurological recovery after hypoxia-ischemia insults.

## Claims

### Claim 1

A system for monitoring and determining neurological outcome of a brain post cardiac arrest (CA), said system comprising:
a. one or more monitoring devices for detecting spreading depolarization (SD) and repolarization (RP) in the brain;
b. a processor operatively coupled to the one or more monitoring devices; and
c. a memory coupled to the processor, said memory storing one or more metrics for determining a neurological outcome score, and computer-readable instructions that, when executed by the processor, causes the processor to perform operations comprising:
i. receiving data on SD and RP from the one or more monitoring devices;
ii. comparing the SD and RP data to the one or more metrics to determine an estimated neurological outcome score; and
iii. identifying a neurological condition of the brain based on the neurological outcome score;
wherein the neurological outcome score is used to gauge severity and prognosticate outcome of the neurological condition of the brain, wherein SD and RP are biomarkers for neurological outcome post-cardiac arrest and resuscitation, respectively, wherein prognostication of the neurological outcome is achieved in real-time.

### Claim 2 (depends on 1)

The system of claim 1, wherein the one or more monitoring devices is an electrophysiological monitoring device for detecting SD and RP in the brain, an optical measurement device for measuring one or more of cerebral blood flow (CBF), tissue oxygenation, and tissue scattering in the brain, a combination thereof, wherein the optical measurement device further detects SD and RP.

### Claim 3 (depends on 2)

The system of claim 2, wherein the electrophysiological monitoring device comprises a plurality of electrodes operatively coupled to a detector.

### Claim 4 (depends on 2)

The system of claim 2, wherein the optical measurement device comprise point measurement devices, diffuse optical measurement devices, or optical measurement devices capable of measuring one or more of CBF, tissue oxygenation, and tissue scattering through intact human skull.

### Claim 5 (depends on 2)

The system of claim 2, wherein the memory further comprises computer-readable instructions that, when executed by the processor, causes the processor to perform operations comprising:
a. receiving measurements of one or more of CBF, tissue oxygenation, and tissue scattering from one or more optical measurement devices;
b. determining one or more of cerebral metabolic rate of oxygen (CMRO2) from the measurements of CBF and tissue oxygenation, and scattering change onset, duration, and magnitude from the tissue scattering measurements; and
c. comparing one or more of the CMRO2, scattering change onset, duration of scattering change, magnitude of scattering change, CBF, and tissue oxygenation measurements to one or more metrics to determine the estimated neurological outcome score.

### Claim 6 (depends on 1)

The system of claim 1 further comprising a means for inducing SD in the brain.

### Claim 7 (depends on 1)

The system of claim 1 further comprising a means for inducing RP in the brain.

### Claim 8 (depends on 1)

The system of claim 1, wherein the one or more metrics are based on measures of neurological status or outcome, wherein said measures is a Glasgow Coma Scale (GCS), Cerebral Performance Category (CPC), a Modified Rankin Scale (mRS), or specific features of a neurological exam.

### Claim 9 (depends on 1)

The system of claim 1, wherein earlier onsets of SD and RP indicate improved neurological outcome.

### Claim 10

A method of improving neurological outcome in a subject during cardiac arrest, comprising:
a. detecting spreading depolarization (SD), or a lack or delay of SD, in a brain of the subject post cardiac arrest;
b. resuscitating the subject;
c. detecting repolarization (RP), or a lack or delay of RP, in the brain of the subject post resuscitation;
d. comparing SD and RP data to one or more metrics to determine an estimated neurological outcome score;
e. identifying a neurological condition of the brain based on the neurological outcome score; and
f. administering a treatment to the subject to improve the neurological condition of the brain;
wherein the neurological outcome score is a gauge of severity and prognosticates outcome of the neurological condition of the brain, wherein SD and RP are biomarkers of neurological outcome post-cardiac arrest and resuscitation, respectively, wherein prognostication of the neurological outcome is achieved in real-time.

### Claim 11 (depends on 10)

The method of claim 10, wherein the treatment comprises therapeutically administering a drug, electrical stimulation, magnetic stimulation, optical stimulation, soundwave-induced stimulation, or a combination thereof.

### Claim 12 (depends on 10)

The method of claim 10 further comprising:
a. measuring one or more of cerebral blood flow (CBF), tissue oxygenation, and tissue scattering in the brain;
b. determining one or more of cerebral metabolic rate of oxygen (CMRO2) from the measurements of CBF and tissue oxygenation, and scattering change onset, duration, and magnitude from the tissue scattering measurements; and
c. comparing one or more of the CMRO2, scattering change onset, duration of scattering change, magnitude of scattering change, CBF, and tissue oxygenation measurements to one or more metrics to determine the estimated neurological outcome score.

### Claim 13 (depends on 12)

The method of claim 12, wherein one or more of the CBF, tissue oxygenation, and tissue scattering are measured by one or more optical measurement devices comprising point measurement devices, diffuse optical measurement devices, or optical measurement devices capable of measuring one or more of the CBF, tissue oxygenation, and tissue scattering through intact human skull.

### Claim 14 (depends on 10)

The method of claim 10, wherein SD and RP are detected by an electroencephalogram (EEG), an electrocorticograph (ECoG), one or more optical measurement devices, or a combination thereof.

### Claim 15 (depends on 10)

The method of claim 10 further comprising inducing SD in the brain during or immediately after cardiac arrest.

### Claim 16 (depends on 10)

The method of claim 10 further comprising inducing RP in the brain during or immediately after resuscitation.

### Claim 17

A method of determining neurological outcome in a subject after cardiac arrest, comprising:
a. detecting spreading depolarization (SD), or a lack or delay of SD, in a brain of the subject post cardiac arrest;
b. detecting repolarization (RP), or a lack or delay of RP, in the brain of the subject post resuscitation;
c. comparing SD and RP data to one or more metrics to determine an estimated neurological outcome score; and
d. identifying a neurological condition of the brain based on the neurological outcome score;
wherein the neurological outcome score is a gauge of severity and prognosticates outcome of the neurological condition of the brain, wherein SD and RP are biomarkers of neurological outcome post-cardiac arrest and resuscitation, respectively, wherein prognostication of the neurological outcome is achieved in real-time.

### Claim 18 (depends on 17)

The method of claim 17 further comprising:
a. measuring one or more of cerebral blood flow (CBF), tissue oxygenation, and tissue scattering in the brain;
b. determining one or more of cerebral metabolic rate of oxygen (CMRO2) from the measurements of CBF and tissue oxygenation, and scattering change onset, duration, and magnitude from the tissue scattering measurements; and
c. comparing one or more of the CMRO2, scattering change onset, duration of scattering change, magnitude of scattering change, CBF, and tissue oxygenation measurements to one or more metrics to determine the estimated neurological outcome score.

### Claim 19 (depends on 17)

The method of claim 17 further comprising inducing SD in the brain during or immediately after cardiac arrest.

### Claim 20 (depends on 17)

The method of claim 17 further comprising inducing RP in the brain during or immediately after resuscitation.
